TrialPath
Recruiting

Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)

NCT07567027 · NYU Langone Health
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR) Trial
About this study
The purpose of this study is to evaluate the feasibility, safety, and potential protective benefit of Barrigel, a hyaluronic acid-based rectal spacer, in patients undergoing prostate cryoablation for localized or recurrent prostate cancer. The primary aim is to assess Barrigel thermal stability during cryoablation.
Eligibility criteria
Inclusion Criteria: * Male patients aged 40-95 years. * Biopsy-confirmed localized prostate cancer (Grade Group ≥ 2). Salvage cryoablation cases may be included. * Unifocal disease visible on multiparametric MRI (mpMRI) and amenable to focal or whole gland cryoablation. * Prostate-specific antigen (PSA) \< 20 ng/ml. * No metastatic disease on Prostate-Specific Membrane Antigen (PSMA) PET/CT, when recommended per National Comprehensive Cancer Network (NCCN) guidelines. * Eligible for and consenting to transperineal cryoablation under anesthesia. * Willingness to comply with post-procedure follow-up, including PSA testing and imaging. * Cryoablation which requires treatment of the posterior prostate as per clinician judgement. Exclusion Criteria: * Evidence of metastatic disease. * Prior radiation therapy to the area of the prostate. * Active rectal or urinary tract infection. * Known allergy to hyaluronic acid products or contrast agents. * Inability to tolerate MRI. * Inability or unwillingness to comply with study follow-up.
Study design
Enrollment target: 20 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-06-17
Estimated completion: 2028-06-01
Last updated: 2026-07-09
Interventions
Device: Barrigel Injectable GelProcedure: Cryoablation
Primary outcomes
  • • Percentage of cases in which Barrigel remains unfrozen (temperature maintained above 0°C throughout the freeze cycles) (End of procedure (up to 4 hours))
Sponsor
NYU Langone Health · other
Contacts & investigators
ContactViola Sulollari · contact · Viola.Sulollari@nyulangone.org · (646) 825-6300
ContactWei Phin Tan, MD · contact · weiphin.tan@nyulangone.org · 646-825-6325
InvestigatorWei Phin Tan, MD · principal_investigator, NYU Langone Health
All locations (1)
NYU Langone HealthRecruiting
New York, New York, United States
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR) · TrialPath